Zhicheng Finance and Economics APP News, Maibo Pharmaceuticals-B (02181) announced that one of the company's core products, the recombinant anti-tumor necrosis factor alpha human-mouse chimeric monoclonal antibody CMAB008 independently developed by the company, has received approval from the Ministry of Health of Peru for the listing registration application of the suspension (injection of infliximab) used to treat: (i) adult ulcerative colitis; (ii) ankylosing spondylitis; (iii) rheumatoid arthritis; (iv) adult and children over 6 years old Crohn's disease; (v) fistulizing Crohn's disease; and (vi) psoriasis.
迈博药业-B(02181)：秘鲁卫生部批准核心产品CMAB008(注射用英夫利西单抗)的上市注册申请
Meibo Pharmaceutical-B (02181): The Peruvian Ministry of Health has approved the market registration application for core product CMAB008 (injection of Enfuvirtide monoclonal antibody).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.